Printer Friendly

A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF EPINEPHRINE MIST

 FORT LEE, N.J., May 6 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today announced that its liquid pharmaceuticals subsidiary, Barre-National, Inc., has received approval from the Food and Drug Administration (FDA) to manufacture and market Epinephrine Mist.
 Epinephrine Mist is a product used to mitigate respiratory distress. Barre's product is the only approved generic equivalent of the over-the- counter brands, Primatene(R) Mist, and Bronkaid(R) Mist, which together have annual sales exceeding $50 million. Barre anticipates marketing the product beginning in the fourth quarter of 1993. This product had annual sales of approximately $4 million for Barre before it was discontinued in 1989 for reformulation. The company believes Epinephrine will be an anchor product in Barre's consumer products line.
 A. L. Laboratories is a multinational manufacturer and marketer of specialized and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington state, Denmark and Indonesia.
 -0- 5/6/93
 /CONTACT: Iris Daniels of A. L. Laboratories, 201-947-7774, or David Walke of Morgen-Walke Associates, 212-986-5900, for A. L. Laboratories/
 (BMD)


CO: A.L. Laboratories, Inc. ST: New Jersey IN: MTC SU:

CK -- NY049 -- 5329 05/06/93 10:35 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1993
Words:201
Previous Article:ISTEC REPORTS STRONG FOURTH QUARTER/YEAR END GAINS
Next Article:NAHAMA & WEAGANT ANNOUNCES A SUCCESSFUL GAS WELL IN ITS SOUTH DAVIS FIELD
Topics:


Related Articles
EMERGENCY TREATMENT KITS RECALLED
A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF CLOTRIMAZOLE VAGINAL CREAM
A. L. LABORATORIES ELABORATES ON SECOND QUARTER EARNINGS RELEASE
A. L. LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
A. L. LABORATORIES ANNOUNCES RECEIPT OF THREE NEW PRODUCT APPROVALS FROM FDA
WHITEHALL-ROBINS HEALTHCARE ISSUES STATEMENT ON PRIMATENE MIST
BARR LABORATORIES LAUNCHES MEGESTROL ACETATE CANCER TREATMENT; FIRST NEW PRODUCT FROM 1994 PORTFOLIO OF DEVELOPMENT CANDIDATES
Barr's First Proprietary Product Receives FDA Approval; Contraceptive Product Co-Developed with Gynetics, Inc.
Barr Launches Generic Hydrea Cancer Treatment.
Alpharma USPD Announces FDA Approval of Cromolyn Sodium Inhalation Solution USP.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters